Press Releases | Association for Accessible Medicines

AAM Welcomes the Re-introduction of the PACED Act

Feb 13, 2019 | Rachel Schwartz

AAM Welcomes Re-Introduction of the PACED Act

Pass CREATES Act - lower prescription drug prices for patients

Feb 8, 2019 | Rachel Schwartz

Statement from the Association for Accessible Medicines on the Introduction of the CREATES Act

Congress Should Reject Hatch-Waxman Act of 2019

Feb 7, 2019 | Rachel Schwartz

AAM: Congress Should Reject Hatch-Waxman Integrity Act of 2019

AAM Announces 2019 Board of Directors

Feb 4, 2019 | Rachel Schwartz

AAM Announces 2019 Board of Directors

Trump Targeting Backdoor Rebates - Lower Drug Prices

Feb 1, 2019 | Rachel Schwartz

AAM Statement on Trump Administration’s Proposal to Lower Drug Costs by Targeting Backdoor Rebates

Pill Bottles

Dec 13, 2018 | Rachel Schwartz

AAM Statement on FDA Withdrawal of Generic Drug Labeling Rule

Dec 10, 2018 | Rachel Schwartz

Andrew O’Connor Joins AAM as Manager, State Government Affairs

AAM Statement on Signing of USMCA by President

Nov 30, 2018 | Rachel Schwartz

AAM Statement on Signing of USMCA by President

Preserve Patient Access in USMCA

Nov 14, 2018 | Rachel Schwartz

Poll Results: Americans’ Attitudes on U.S. Trade Policy and Drug Pricing

Patient Groups, Retirees, American Workers, Doctors, Manufacturers, Join to Voice Concern Over Proposed Trade Deal

Nov 5, 2018 | Rachel Schwartz

Patient Groups, Retirees, American Workers, Doctors, Manufacturers, Join to Voice Concern Over Proposed Trade Deal

Supreme Court

Oct 17, 2018 | Rachel Schwartz

AAM Files Amicus Brief in Helsinn v Teva

Applauding Nomination of Dr. Scott Gottlieb to Lead the FDA

Oct 11, 2018 | Rachel Schwartz

AAM Statement on FDA Record Generic Approvals